Canada - English - Health Canada

angita pharma inc. - lacosamide - tablet - 150mg - lacosamide 150mg - miscellaneous anticonvulsants

Canada - English - Health Canada

angita pharma inc. - lacosamide - tablet - 200mg - lacosamide 200mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 50mg - lacosamide 50mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 100mg - lacosamide 100mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 150mg - lacosamide 150mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 200mg - lacosamide 200mg - miscellaneous anticonvulsants

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; colloidal anhydrous silica; magnesium stearate; crospovidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; hyprolose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin; indigo carmine aluminium lake - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hyprolose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; magnesium stearate; crospovidone; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.